Universe Pharmaceuticals INC Authorized as The International Branch of National Engineering Technology Research Center
March 22 2022 - 08:00AM
GlobeNewswire Inc.
Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a
pharmaceutical producer and distributor in China, today announced
that the Company has been authorized as an International Branch
(the “Branch”) of the National Engineering Technology Research
Center for Modernization of Traditional Chinese Medicine (the
“Center”), a Chinese medicine industry research center approved by
the Ministry of Science and Technology of China. As an authorized
International Branch, the Company will be allowed to join the
Center’s strong network and share its extensive industrial
recourses, and such authorization demonstrates industry’s
recognition of the Company's capabilities.
The Company hosted the authorization ceremony
and reception for government and industry representatives on March
11, 2022 in Ji’an, China. Participants of this ceremony included
Mr. Xiaodong Zhu, Deputy Mayor of Ji’an government, Mr. Runjin
Peng, Mayor of the Ji’an county, Mr. Hui Cao, Director of the
Center, Mr. Ming Yang, Professor and Vice President of Jiangxi
University of Traditional Chinese Medicine, Mr. Gang Lai, Chairman
and CEO of the Company, Mr. Yajun Hu, Vice President of the
Company, and Mr. Ichiri Nishimura, Foreign Expert of the Company
and Director of the Branch.
Through leveraging the Center’s technologies and
utilizing the Company's research and development capacity, the
Company has determined to focus its research and development
efforts on traditional Chinese medicine, Kampo medicine, Chinese
medicine formula granules, and Chinese medicine essential oils. The
Company strives to enhance its brand recognition and market
position as a pharmaceutical company that serves middle-aged and
elderly people.
Under the guidance of the Center, the Company
expects to implement a series of new measures, integrate resources,
and improve communications with other biopharmaceutical companies,
and the Company intends to make contributions to the
internationalization of traditional Chinese medicine.
Mr. Gang Lai, Chairman and CEO of Universe
Pharmaceuticals INC, commented, “We are excited to be authorized as
a Branch from the Center, which is a key milestone for the Company
as we are recognized by the experts in the traditional Chinese
medicine industry and supported by the Ji’an government. With the
integration of resources and support from these parties, we will
further work on developing additional types of traditional Chinese
medicine and increase our efforts to emerge as a leader in the
industry.”
About Universe Pharmaceuticals
INC
Universe Pharmaceuticals INC, headquartered in
Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor
in China. The Company specializes in the manufacturing, marketing,
sales and distribution of traditional Chinese medicine derivatives
products targeting the elderly with the goal of addressing their
physical conditions in the aging process and to promote their
general well-being. The Company also distributes and sells
biomedical drugs, medical instruments, Traditional Chinese Medicine
Pieces, and dietary supplements manufactured by third-party
pharmaceutical companies. Currently, the Company’s products are
sold in 30 provinces of China. For more information, visit the
Company’s website at http://www.universe-pharmacy.com/.
Forward-Looking Statements
All statements other than statements of
historical fact in this announcement are forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages
investors to review other factors that may affect its future
results in the Company’s registration statement and in its other
filings with the SEC.
For more information, please contact:
Ascent Investors Relations LLCTina
XiaoPresidentPhone:
917-609-0333Email: tina.xiao@ascent-ir.com
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From May 2023 to Jun 2023
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Jun 2022 to Jun 2023